Volume 29, Number 4—April 2023
CME ACTIVITY - Synopsis
Nocardia pseudobrasiliensis Co-infection in SARS-CoV-2 Patients
Table 1
Reported susceptibility of Nocardia pseudobrasiliensis bacteria to antimicrobial drugs*
Antimicrobial drug | This study | Case 1† | Case 2† | Case 3† | Case 4† | Case 5† | Case 6† | Case 7‡ |
---|---|---|---|---|---|---|---|---|
Amikacin | S | R | S | II | S | S | S | VSR or II |
Amoxi-clav | R | R | II | S | R | R | R | R |
Ceftriaxone | I | R | R | II | S | S | R | VSR or II |
Ciprofloxacin | S | S | S | S | S | S | S | II |
Clarithromycin | S | S | II | S | S | S | S | S |
Doxycycline | R | R | II | II | II | R | R | II |
Imipenem | R | R | R | R | II | R | R | VSR or II |
Linezolid | S | S | S | II | II | S | S | S |
Minocycline | R | R | II | II | M | R | R | II |
Moxifloxacin | S | S | II | II | II | S | II | II |
Tobramycin | S | II | II | II | II | II | II | II |
TMP/SMX | S | R | R | II | S§ | R | S | S |
*Amoxi-clav, amoxicilline/clavulanic acid; I, intermediate; II, insufficient information; M, moderate; R, resistant; S, susceptible; TMP/SMX, trimethoprim/sulfamethoxazole; VSR, variable susceptibility results. †Veerappan Kandasamy et al. (2). ‡Wilson et al. (3). §This specimen was susceptible to SMX only.
References
- Wallace RJ Jr, Brown BA, Blacklock Z, Ulrich R, Jost K, Brown JM, et al. New Nocardia taxon among isolates of Nocardia brasiliensis associated with invasive disease. J Clin Microbiol. 1995;33:1528–33. DOIPubMedGoogle Scholar
- Veerappan Kandasamy V, Nagabandi A, Horowitz EA, Vivekanandan R. Multidrug-resistant Nocardia pseudobrasiliensis presenting as multiple muscle abscesses. BMJ Case Rep. 2015;2015:
bcr2014205262 . DOIPubMedGoogle Scholar - Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc. 2012;87:403–7. DOIPubMedGoogle Scholar
- Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol. 2003;41:4497–501. DOIPubMedGoogle Scholar
- Colaneri M, Lupi M, Sachs M, Ludovisi S, Di Matteo A, Pagnucco L, et al. A challenging case of SARS-CoV-2- AIDS and nocardiosis coinfection from the SMatteo COvid19 REgistry (SMACORE). New Microbiol. 2021;44:129–34.PubMedGoogle Scholar
- Arif M, Talon A, Sarma H, Munoz J, Charley E. Nocardia after COVID-19 infection. Chest. 2021;160(Supplement):A429. DOIGoogle Scholar
- Atemnkeng F, Ducey J, Khalil A, Elemam A, Diaz K. Diagnosing disseminated nocardiosis in a patient with COVID-19 pneumonia. J Med Cases. 2021;12:319–24. DOIPubMedGoogle Scholar
- Kaur T, Bhatti W. Complications of high-dose steroids in COVID-19. Chest. 2021;160(Supplement):A490. DOIGoogle Scholar
- Driscoll S, Carroll WD, Nichani S, Fishwick R, Bakewell K, Gilchrist FJ. COVID-19 infection and nocardiosis causing the death of an adolescent with cystic fibrosis. Pediatr Pulmonol. 2022;57:1823–5. DOIPubMedGoogle Scholar
- Cicero MN, Memmo AI, Piccionello IR, Seminara G, Benfante A, Scichilone NA. 79-year-old-man with SARS-CoV-2 pneumonia and unusual pulmonary coinfection. Minerva Respir Med. 2022;61:86–91. DOIGoogle Scholar
- Veličković J, Vukičević TA, Spurnić AR, Lazić I, Popović B, Bogdanović I, et al. Case report: Nocardial brain abscess in a persistently SARS-CoV-2 PCR positive patient with systemic lupus erythematosus. Front Med (Lausanne). 2022;9:
973817 . DOIPubMedGoogle Scholar - DiMeglio M, Shaikh H, Newman J, Vazsquez-Rubio G. Nocardiosis of the Central Nervous System: A rare complication of COVID management? IDCases. 2022;29:
e01599 . DOIPubMedGoogle Scholar - Laplace M, Flamand T, Ion C, Gravier S, Zadeh MM, Debriel D, et al. Pulmonary nocardiosis as an opportunistic infection in COVID-19. Eur J Case Rep Intern Med. 2022;9:
003477 . DOIPubMedGoogle Scholar - Toyokawa M, Ohana N, Ueda A, Imai M, Tanno D, Honda M, et al. Identification and antimicrobial susceptibility profiles of Nocardia species clinically isolated in Japan. Sci Rep. 2021;11:16742. DOIPubMedGoogle Scholar
- Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al.; COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83–8. DOIPubMedGoogle Scholar
- Søvik S, Barrat-Due A, Kåsine T, Olasveengen T, Strand MW, Tveita AA, et al. Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. J Infect. 2022;85:57–63. DOIPubMedGoogle Scholar
- Paget C, Trottein F. Mechanisms of bacterial superinfection post-influenza: a role for unconventional T cells. Front Immunol. 2019;10:336. DOIPubMedGoogle Scholar
- Chong WH, Saha BK, Ananthakrishnan Ramani , Chopra A. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection. 2021;49:591–605. DOIPubMedGoogle Scholar
- Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al.; ISARIC4C investigators. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021;2:e354–65. DOIPubMedGoogle Scholar
Page created: February 01, 2023
Page updated: March 22, 2023
Page reviewed: March 22, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.